Eloxx Pharmaceuticals doses patients: what it means for ELOX stock
Published on 10/05/2026 at 04:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Eloxx Pharmaceuticals announced first patients dosed in its Phase 2b EXACT study of exaluren for nonsense mutation Alport syndrome in September 2026, giving ELOX stock a clinical milestone to assess. StockTitan lists the dosing announcement among the company updates dated September 11, 2026.
EXACT study sets the near-term test
The study targets a rare kidney disease caused by nonsense mutations, while exaluren is being developed as a ribosome-modulating treatment. Yahoo Finance describes exaluren as a Phase 2 candidate for Alport syndrome, cystic fibrosis and nephropathic cystinosis.
The clinical milestone does not yet create product revenue. Eloxx reported USD 0.00 revenue and a net loss of USD 4.50 million in the second quarter of 2026, with diluted earnings per share of minus USD 0.66, according to MarketBeat on August 11, 2026.
Cash gives the pipeline room
Eloxx held USD 61.96 million in cash and cash equivalents as of June 30, 2026. That balance compares with USD 6.36 million at March 31, 2026, making financing and clinical execution central to the investment case.
The company is a clinical-stage biotechnology business focused on rare and ultra-rare genetic diseases. Its lead programs depend on successful trials, regulatory progress and additional development funding before commercial sales can begin.
Next report arrives November 11
Investing.com lists November 11, 2026 as the next earnings date. The report should give investors a new read on cash usage, trial progress and the funding runway.
On Nasdaq, ELOX stood at USD 15.51 on October 2, 2026, down USD 0.20, or 1.27 percent, from the prior close of USD 15.71. The stock's USD 8.20 to USD 23.40 52-week range places the latest price USD 7.89, or 33.72 percent, below the high. Market capitalization was USD 53.3 million on that date.
Eloxx Pharmaceuticals market snapshot
- Company: Eloxx Pharmaceuticals, Inc.
- Ticker: ELOX
- Primary exchange: Nasdaq
- Market capitalization: USD 53.3 million (as of October 2, 2026)
- 52-week range: USD 8.20-23.40 (as of October 2, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 11, 2026
